GLAXOSMITHKLINE PHARMACEUTICALS
|
GLAXOSMITHKLINE PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 36.05 | 100.04 | 21.14 | 5.50 | 26.29 |
CEPS(Rs) | 39.75 | 26.50 | 21.60 | 10.38 | 29.16 |
DPS(Rs) | 32.00 | 90.00 | 30.00 | 40.00 | 20.00 |
Book NAV/Share(Rs) | 102.89 | 157.19 | 87.26 | 107.47 | 126.31 |
Tax Rate(%) | 27.35 | 51.12 | 36.72 | 69.52 | 34.76 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 22.54 | 21.20 | 19.14 | 19.55 | 19.21 |
EBIT Margin(%) | 23.49 | 21.73 | 14.64 | 9.28 | 21.84 |
Pre Tax Margin(%) | 23.44 | 21.67 | 14.53 | 9.09 | 21.82 |
PAT Margin (%) | 17.03 | 10.59 | 9.19 | 2.77 | 14.24 |
Cash Profit Margin (%) | 18.87 | 12.49 | 11.71 | 5.23 | 15.79 |
Performance Ratios | |||||
ROA(%) | 15.76 | 10.11 | 9.52 | 1.72 | 5.77 |
ROE(%) | 27.58 | 18.39 | 17.42 | 4.71 | 21.22 |
ROCE(%) | 38.06 | 37.72 | 27.74 | 15.76 | 32.54 |
Asset Turnover(x) | 0.93 | 0.95 | 1.04 | 0.62 | 0.41 |
Sales/Fixed Asset(x) | 5.75 | 6.03 | 3.04 | 3.34 | 6.48 |
Working Capital/Sales(x) | 3.06 | 1.79 | 4.68 | 4.47 | 5.67 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.17 | 0.17 | 0.33 | 0.30 | 0.15 |
Receivable days | 20.34 | 21.37 | 18.42 | 11.96 | 15.60 |
Inventory Days | 50.87 | 54.91 | 60.14 | 52.62 | 57.56 |
Payable days | 143.05 | 140.69 | 119.53 | 106.45 | 122.52 |
Valuation Parameters | |||||
PER(x) | 36.73 | 16.62 | 68.13 | 226.34 | 49.44 |
PCE(x) | 33.31 | 62.75 | 66.69 | 119.94 | 44.58 |
Price/Book(x) | 12.87 | 10.58 | 16.51 | 11.59 | 10.29 |
Yield(%) | 2.42 | 5.41 | 2.08 | 3.21 | 1.54 |
EV/Net Sales(x) | 6.54 | 7.84 | 7.94 | 6.21 | 6.67 |
EV/Core EBITDA(x) | 23.51 | 30.67 | 32.80 | 27.18 | 29.65 |
EV/EBIT(x) | 25.38 | 32.89 | 50.80 | 64.12 | 30.52 |
EV/CE(x) | 6.66 | 5.68 | 7.72 | 6.62 | 2.67 |
M Cap / Sales | 6.90 | 8.59 | 8.34 | 6.54 | 7.04 |
Growth Ratio | |||||
Net Sales Growth(%) | -0.80 | 12.05 | -9.27 | 3.08 | 8.94 |
Core EBITDA Growth(%) | 8.03 | 18.19 | -3.74 | 4.71 | 25.48 |
EBIT Growth(%) | 7.32 | 70.71 | 46.60 | -54.32 | 26.49 |
PAT Growth(%) | 59.58 | 32.55 | 208.21 | -79.07 | 26.99 |
EPS Growth(%) | -63.97 | 373.19 | 284.26 | -79.07 | -36.50 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | - | - | - | - | - |
Current Ratio(x) | 1.88 | 2.18 | 1.49 | 1.74 | 1.20 |
Quick Ratio(x) | 1.53 | 1.87 | 1.09 | 1.26 | 1.02 |
Interest Cover(x) | 462.54 | 391.29 | 129.56 | 49.26 | 1,232.59 |
Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of GLAXOSMITHKLINE PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLAXOSMITHKLINE PHARMACEUTICALS | ₹35,355.5 Cr | 0.4% | 10.9% | 71.1% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹360,452.0 Cr | 1.1% | -6.6% | 56.7% | Stock Analytics | |
CIPLA | ₹113,132.0 Cr | 0.2% | -4.4% | 54.3% | Stock Analytics | |
DIVIS LABORATORIES | ₹106,191.0 Cr | 4.8% | 18.9% | 23.9% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹103,512.0 Cr | 4.3% | 2.6% | 29.9% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹95,954.5 Cr | 2.2% | -4.6% | 86.6% | Stock Analytics |
GLAXOSMITHKLINE PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLAXOSMITHKLINE PHARMACEUTICALS | 0.4% |
10.9% |
71.1% |
SENSEX | 1% |
2.8% |
23.9% |
You may also like the below Video Courses